Last 47 quarters of trend data · Healthcare · Vaccines & Infectious Disease
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.48 | — | — | 7.97 | — | — | — | — | — | — | — | — | — | — | 0.02 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1523.89 | — | — | — | — | — | 240.81 | 126.93 | — | 545.24 | — | 339.73 | 67.42 | 131.61 | 460.92 | 802.96 | 141.37 | 1556.73 | 11844.80 | 3751.89 | 15486.39 |
| — | — | — | — | — | — | — | -62.6% | — | +314.3% | — | -57.7% | -52.3% | -91.5% | -96.1% | -78.6% | -99.1% | -92.7% | -22.0% | +376.9% | -39.7% | |
| P/B Ratio | 2.37 | 20.54 | 19.82 | 4.98 | — | 2.78 | 1.23 | 0.87 | 2.21 | 2.27 | 3.42 | 1.19 | 0.76 | 0.70 | 1.06 | 1.80 | 19.41 | 16.41 | 26.56 | 31.51 | 39.84 |
| — | +639.8% | +1513.5% | +474.6% | — | +22.2% | -64.1% | -27.1% | +191.7% | +223.4% | +221.8% | -34.0% | -96.1% | -95.7% | -96.0% | -94.3% | -51.3% | -64.2% | -31.5% | -17.3% | -46.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 5.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | — | — | — | 100.0% | -563.1% | — | -722.4% | — | -70.7% | 100.0% | 100.0% | -902.3% | -981.7% | 100.0% | 100.0% | 100.0% | -64.4% | 100.0% |
| — | — | — | — | — | — | — | -696.5% | — | -822.4% | — | +92.8% | 0.0% | 0.0% | -1002.3% | -1425.3% | 0.0% | 0.0% | 0.0% | +82.7% | 0.0% | |
| Operating Margin | -132871.3% | — | — | — | — | — | -38337.0% | -17410.8% | — | -32945.9% | — | -26686.3% | -9152.6% | -16392.0% | -38238.2% | -44876.8% | -390.6% | -13276.1% | -36033.3% | -12573.8% | -20553.2% |
| — | — | — | — | — | — | — | +34.8% | — | -101.0% | — | +40.5% | -2243.2% | -23.5% | -6.1% | -256.9% | +98.1% | +56.5% | -154.5% | -2291.6% | -33.6% | |
| Net Margin | -130000.0% | — | — | — | — | — | -30140.5% | -16566.4% | — | -31993.3% | — | -24357.9% | -8734.8% | -15725.3% | -35364.8% | -43687.2% | -412.8% | -13832.0% | -39720.8% | -12745.3% | -20627.2% |
| — | — | — | — | — | — | — | +32.0% | — | -103.5% | — | +44.2% | -2016.2% | -13.7% | +11.0% | -242.8% | +98.0% | +54.1% | -171.0% | -2822.4% | -354.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -183.5% | -115.2% | -130.5% | 46.0% | -437.2% | -59.0% | -32.9% | -27.3% | -29.6% | -33.7% | -28.8% | -19.6% | -22.1% | -19.3% | -19.3% | -22.3% | -13.4% | -33.2% | -21.0% | -25.1% | -12.5% |
| — | -95.4% | -296.8% | +268.5% | -1379.3% | -74.8% | -14.3% | -39.4% | -34.0% | -74.9% | -49.2% | +12.1% | -64.8% | +42.0% | +8.0% | +11.2% | -7.1% | -120.6% | -100.8% | -304.4% | -266.5% | |
| ROA | -90.6% | -12.1% | -31.7% | 5.2% | -66.1% | -30.2% | -19.6% | -17.6% | -20.9% | -24.5% | -20.3% | -13.7% | -15.9% | -14.2% | -13.2% | -14.7% | -8.9% | -24.0% | -16.8% | -20.7% | -10.7% |
| — | +59.9% | -61.5% | +129.8% | -216.4% | -23.3% | +3.3% | -28.1% | -31.2% | -72.4% | -53.7% | +6.6% | -79.4% | +40.7% | +21.3% | +29.0% | +16.8% | -82.0% | -84.4% | -316.4% | -345.2% | |
| ROIC | -3476.2% | — | — | — | — | -92.5% | -101.1% | -38.7% | -29.4% | -30.4% | -21.3% | -14.6% | -18.0% | -15.9% | -16.1% | -17.3% | -9.5% | -25.2% | -15.6% | -20.3% | -10.0% |
| — | — | — | — | — | -203.8% | -374.3% | -166.3% | -63.4% | -91.5% | -32.7% | +15.9% | -90.1% | +37.0% | -3.2% | +14.7% | +5.1% | -105.1% | -54.3% | -116.3% | +46.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.39 | 1.83 | 1.43 | 0.39 | — | 0.37 | 0.22 | 0.17 | 0.17 | 0.13 | 0.14 | 0.26 | 0.22 | 0.18 | 0.16 | 0.14 | 0.12 | 0.11 | 0.09 | 0.08 | 0.07 |
| — | +390.0% | +551.6% | +124.5% | — | +178.4% | +54.7% | -32.7% | -21.5% | -26.1% | -9.1% | +78.5% | +77.4% | +62.3% | +65.1% | +74.6% | +66.4% | +68.4% | +62.5% | -2.4% | -68.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.40 | 1.00 | 1.04 | 1.40 | 0.79 | 1.66 | 2.63 | 2.77 | 3.88 | 4.45 | 4.77 | 3.60 | 4.00 | 3.91 | 4.24 | 3.25 | 3.69 | 3.18 | 6.74 | 6.82 | 9.49 |
| — | -39.8% | -60.5% | -49.5% | -79.7% | -62.7% | -44.9% | -23.0% | -2.8% | +13.8% | +12.5% | +10.5% | +8.4% | +23.3% | -37.0% | -52.3% | -61.1% | -69.7% | -52.4% | -39.6% | +3.8% | |
| Quick Ratio | 1.40 | 1.00 | 1.04 | 1.40 | 0.79 | 1.66 | 2.63 | 2.77 | 3.88 | 4.45 | 4.77 | 3.60 | 4.00 | 3.91 | 4.24 | 3.25 | 3.69 | 3.18 | 6.74 | 6.82 | 9.49 |
| — | -39.8% | -60.5% | -49.5% | -79.7% | -62.7% | -44.9% | -23.0% | -2.8% | +13.8% | +12.5% | +10.5% | +8.4% | +23.3% | -37.0% | -52.3% | -61.1% | -69.7% | -52.4% | -39.6% | +3.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -170.34 | -87.56 | -107.23 | -112.35 | -128.67 | -172.73 | -119.53 | -345.10 | -244.33 | -221.66 | -125.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INO stock.
Inovio Pharmaceuticals, Inc.'s current P/E is -1.5x. The average P/E over the last 1 quarters is 8.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Inovio Pharmaceuticals, Inc.'s current operating margin is -132871.3%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Inovio Pharmaceuticals, Inc.'s business trajectory between earnings reports.